Pharma-Bio Serv details 2026 vote results

Pharma-Bio Serv, Inc. reported the results of its 2026 Annual Meeting of Stockholders.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Pharma-Bio Serv, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders elected Irving Wiesen as a Class I director to serve until the 2029 Annual Meeting, with 10,208,071 votes for and 195,625 votes withheld, plus 2,839,645 broker non-votes. Stockholders also ratified the selection of Crowe PR PSC as independent certified public accountants for the fiscal year ending October 31, 2026, with 13,241,794 votes for, 3 against and 1,544 abstentions.

8-K Event Classification

Item 9.01 — Financial Statements and Exhibits

1 item

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Votes for director: 10,208,071 votes Votes withheld for director: 195,625 votes Broker non-votes on director election: 2,839,645 votes +3 more

6 metrics

Votes for director 10,208,071 votes Votes for Irving Wiesen as Class I director

Votes withheld for director 195,625 votes Votes withheld on Irving Wiesen election

Broker non-votes on director election 2,839,645 votes Director election proposal broker non-votes

Votes for auditor ratification 13,241,794 votes Ratification of Crowe PR PSC for FY ending Oct 31, 2026

Votes against auditor ratification 3 votes Opposed Crowe PR PSC ratification

Abstentions on auditor ratification 1,544 votes Abstained on Crowe PR PSC ratification proposal

Key Terms

Annual Meeting of Stockholders, broker non-votes, independent certified public accountants, Emerging growth company

4 terms

Annual Meeting of Stockholders financial

"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."

broker non-votes financial

"There were 2,839,645 broker non-votes on this proposal."

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent certified public accountants financial

"Crowe PR PSC as the Company's independent certified public accountants"

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pharma-Bio Serv (PBSV) shareholders vote on at the 2026 Annual Meeting?

Shareholders voted on two key items: electing Irving Wiesen as a Class I director and ratifying Crowe PR PSC as independent certified public accountants for the fiscal year ending October 31, 2026, with detailed vote tallies reported for each proposal.

How many votes did Irving Wiesen receive in the Pharma-Bio Serv (PBSV) director election?

Irving Wiesen received 10,208,071 votes for and 195,625 votes withheld. There were also 2,839,645 broker non-votes recorded on this proposal, and he was elected as a Class I director to serve until the 2029 Annual Meeting of Stockholders.

Was the auditor ratification for Pharma-Bio Serv (PBSV) approved at the 2026 meeting?

Yes, shareholders ratified Crowe PR PSC as independent certified public accountants. The proposal received 13,241,794 votes for, 3 votes against and 1,544 abstentions, with no broker non-votes reported on this ratification item for the 2026 fiscal year.

What is the term length for Pharma-Bio Serv (PBSV) director Irving Wiesen?

Irving Wiesen was elected as a Class I director to serve until the 2029 Annual Meeting of Stockholders. He will continue in this role until that meeting or until his successor is duly elected and qualified, consistent with the company’s governance structure.

Were there broker non-votes on Pharma-Bio Serv (PBSV) 2026 shareholder proposals?

There were 2,839,645 broker non-votes on the proposal to elect Irving Wiesen as director. The auditor ratification proposal for Crowe PR PSC reported no broker non-votes, indicating all such shares were voted or abstained on that specific item.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/15/2026 - 05:02 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 15, 2026

Pharma-Bio Serv, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-50956

20-0653570

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

PO Box 1049, Dorado, Puerto Rico		00646
(Address of principal executive offices)		(Zip Code)

Registrant’s Telephone number, including area code (787) 278-2709

____________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 15, 2026, Pharma-Bio Serv, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Below is a summary of the proposals and corresponding votes.

Irving Wiesen was elected as a Class I director to serve for a term until the 2029 Annual Meeting of Stockholders or until his successor is duly elected and qualified. Irving Wiesen received the following votes:

Nominee	Votes For	Votes Withheld
Irving Wiesen	10,208,071	195,625

There were 2,839,645 broker non-votes on this proposal.

The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2026 received the following votes:

Votes For	Votes Against	Abstain
13,241,794	3	1,544

There were no broker non-votes on this proposal.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PHARMA-BIO SERV, INC.

Date: May 15, 2026	By:	/s/ Pedro J. Lasanta
		Pedro J. Lasanta
		Chief Financial Officer, Vice President Finance and Administration and Secretary

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents